Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma

Cancer

Volumn 101, Issue 10, 2004, Pages 2257-2260

  Kim, Dong Wan ^a   Jo, Yo Han ^a   Jee, Hyun Kim ^a   Wu, Hong Gyun ^a   Chae, Seo Rhee ^a   Chol, Hee Lee ^a   Kim, Tae You ^a   Dae, Seog Heo ^a   Bang, Yung Jue ^a   Noe, Kyeong Kim ^a  

^a Seoul National University   (South Korea)

Author keywords

Chemotherapy; Cisplatin; Esthesioneuroblastoma; Etoposide; Ifosfamide; Olfactory neuroblastoma

Indexed keywords

CISPLATIN; ETOPOSIDE; IFOSFAMIDE; MESNA;

ADULT; ALOPECIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ESTHESIONEUROBLASTOMA; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC DISEASE; HUMAN; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; REMISSION; SURVIVAL RATE; SURVIVAL TIME; TUMOR BIOPSY;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; ESTHESIONEUROBLASTOMA, OLFACTORY; ETOPOSIDE; FEMALE; HUMANS; IFOSFAMIDE; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NASAL CAVITY; NEOADJUVANT THERAPY; NOSE NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 7644224729     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20648     Document Type: Article

References (14)

1. Kadish S, Goodman M, Wang CC. Olfactory neuroblastoma: a clinical analysis of 17 cases. Cancer. 1976;37:1571-1576.
2. Elkon D, Hightower SI, Lim ML, Cantrell RW, Constable WC. Esthesioneuroblastoma. Cancer. 1979;44:1087-1094.
3. Biller HF, Lawson W, Sachdev VP, Som P. Esthesioneuroblastoma: surgical treatment without radiation. Laryngoscope. 1990;100:1199-1201.
4. Levine PA, McLean WC, Cantrell RW. Esthesioneuroblastoma: the University of Virginia experience 1960-1985. Laryngoscope. 1986;96:742-746.
5. Foote RL, Morite A, Ebersold MJ, et al. Esthesioneuroblastoma: the role of adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 1993;27:835-842.
6. Chamberlain MC. Treatment of intracranial metastatic esthesioneuroblastoma. J Clin Oncol. 2002;20:357-358.
7. Polin RS, Sheehan JP, Chenelle AG, et al. The role of preoperative adjuvant treatment in the management of esthesioneuroblastoma: the University of Virginia experience. Neurosurgery. 1998;42:1029-1037.
8. McElroy EA, Buckner JC, Lewis JE. Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience. Neurosurgery. 1998;42:1023-1027.
9. Boni C, Cocconi G, Bisagni G, Ceci G, Peracchia G. Cisplatin and etoposide (VP-16) as a single regimen for small cell lung cancer: a Phase II trial. Cancer. 1989;63:638-642.
10. Loehrer PJ Sr., Ansari R, Gonin R, et al. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol. 1995;13:2594-2599.
11. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
13. Wade PM, Smith RE, Johns ME. Response of esthesioneuroblastoma to chemotherapy. Cancer. 1984;53:1036-1041.
14. Goldsweig HG, Sundaresan N. Chemotherapy of recurrent esthesioneuroblastoma: case report and review of literature. Am J Clin Oncol. 1990;13:139-143.